Cepheid Reaffirms FY 2012 Guidance; Lowers FY 2012 EPS Guidance

Cepheid announced that for fiscal 2012, it expects total revenue to be approximately $333 million, Net loss per share in the range of $(0.42)-$(0.40) and non-GAAP net income per share in the range of $0.21-$0.23. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of...

Thursday, 18 Oct 2012 04:06pm EDT

Boston Scientific Corp Issues Q4 2012 Guidance; Revenue Guidance In Line With Analysts' Estimates; Lowers FY 2012 Revenue Guidance; Narrows FY 2012 EPS Guidance

Boston Scientific Corp announced that for fourth quarter of 2012, it expects sales in a range of $1.740 billion to $1.815 billion. The Company estimates earnings on a GAAP basis in a range of $0.06 to $0.09 per share. Adjusted earnings, excluding acquisition- and restructuring-related charges and...

Thursday, 18 Oct 2012 07:00am EDT

Topspin Medical Inc Appoints New Chief Executive Officer, Mr. Kfir Tamar

Topspin Medical Inc announced that its Board of Directors has appointed a new Chief Executive Officer, Mr. Kfir Tamar, with effect from October 17, 2012.

Wednesday, 17 Oct 2012 08:00pm EDT

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.